Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 20, 2013, Pages 8176-8181

  Yu, Kuan Ping ^a   Heston, Lee ^a   Park, Richard ^a   Ding, Zhaowei ^a   Wang'ondu, Ruth ^a   Delecluse, Henri Jacques ^b   Miller, George ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; DNA; PROTEIN C FOS; PROTEIN C JUN; SERINE;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; DNA METHYLATION; EPSTEIN BARR VIRUS; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; BURKITT LYMPHOMA; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, VIRAL; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; TRANS-ACTIVATORS; VIRUS LATENCY;

EID: 84877843244     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301577110     Document Type: Article

References (41)

1. Landschulz WH, Johnson PF, McKnight SL (1988) The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 240(4860):1759-1764.
2. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T (1989) Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8(1):127-132. (Pubitemid 19273954)
3. Flemington E, Speck SH (1990) Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues. Proc Natl Acad Sci USA 87(23):9459-9463. (Pubitemid 120030646)
4. Kouzarides T, Packham G, Cook A, Farrell PJ (1991) The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 6(2):195-204. (Pubitemid 21902663)
5. Petosa C, et al. (2006) Structural basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein. Mol Cell 21(4):565-572. (Pubitemid 43228011)
6. Bohmann D, et al. (1987) Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238(4832):1386-1392. (Pubitemid 18015958)
7. Vogt PK, Bos TJ, Doolittle RF (1987) Homology between the DNA-binding domain of the GCN4 regulatory protein of yeast and the carboxyl-terminal region of a protein coded for by the oncogene jun. Proc Natl Acad Sci USA 84(10):3316-3319. (Pubitemid 17085394)
8. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD (1990) The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virusinfected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol 64(3):1143-1155. (Pubitemid 20087752)
9. Lehman AM, Ellwood KB, Middleton BE, Carey M (1998) Compensatory energetic relationships between upstream activators and the RNA polymerase II general transcription machinery. J Biol Chem 273(2):932-939. (Pubitemid 28049187)
10. Bishop JM (1981) Enemies within: The genesis of retrovirus oncogenes. Cell 23(1):5-6. (Pubitemid 11173602)
11. Kolman JL, Taylor N, Gradoville L, Countryman J, Miller G (1996) Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J Virol 70(3):1493-1504. (Pubitemid 26062907)
12. Glover JN, Harrison SC (1995) Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature 373(6511):257-261.
13. Fujii Y, Shimizu T, Toda T, Yanagida M, Hakoshima T (2000) Structural basis for the diversity of DNA recognition by bZIP transcription factors. Nat Struct Biol 7(10):889-893.
14. Francis AL, Gradoville L, Miller G (1997) Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency. J Virol 71(4):3054-3061. (Pubitemid 27119950)
15. Adamson AL, Kenney SC (1998) Rescue of the Epstein-Barr virus BZLF1 mutant, Z (S186A), early gene activation defect by the BRLF1 gene product. Virology 251(1): 187-197. (Pubitemid 28527730)
16. Francis A, Ragoczy T, Gradoville L, El-Guindy A, Miller G (1999) Amino Acid substitutions reveal distinct functions of serine 186 of the ZEBRA protein in activation of lytic cycle genes and synergy with the EBV Rta transactivator. J Virol 73(6):4543-4551. (Pubitemid 29246711)
17. Ernberg I, et al. (1989) The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 70(Pt 11):2989-3002. (Pubitemid 19283617)
18. Schaefer BC, Strominger JL, Speck SH (1997) Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol 17(1):364-377. (Pubitemid 26425626)
19. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC (2004) The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 36(10):1099-1104. (Pubitemid 41184472)
20. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC (2005) BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol 79(12):7338-7348. (Pubitemid 40756769)
21. Feederle R, et al. (2000) The Epstein-Barr virus lytic program is controlled by the cooperative functions of two transactivators. EMBO J 19(12):3080-3089. (Pubitemid 30386778)
22. Nakabeppu Y, Ryder K, Nathans D (1988) DNA binding activities of three murine Jun proteins: Stimulation by Fos. Cell 55(5):907-915.
23. Quinlivan EB, et al. (1993) Direct BRLF1 binding is required for cooperative BZLF1/ BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res 21(14):1999-2007. (Pubitemid 23178921)
24. Rowe M, et al. (2007) Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA 104(9):3366-3371. (Pubitemid 46364165)
25. Chen MR, Chang SJ, Huang H, Chen JY (2000) A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J Virol 74(7):3093-3104. (Pubitemid 30143732)
26. Rennekamp AJ, Lieberman PM (2011) Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J Virol 85(6):2837-2850.
27. El-Guindy AS, Miller G (2004) Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol 78(14):7634-7644. (Pubitemid 38915910)
28. Ragoczy T, Miller G (1999) Role of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol 73(12):9858-9866.
29. Serio TR, Kolman JL, Miller G (1997) Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis. J Virol 71(11): 8726-8734. (Pubitemid 27446455)
30. Ragoczy T, Heston L, Miller G (1998) The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72(10):7978-7984. (Pubitemid 28421790)
31. El-Guindy A, Ghiassi-Nejad M, Golden S, Delecluse HJ, Miller G (2013) Essential role of Rta in lytic DNA replication of Epstein-Barr virus. J Virol 87(1):208-223.
32. Kalla M, Göbel C, HammerschmidtW(2012) The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. J Virol 86(1):447-458.
33. Ragoczy T, Miller G (2001) Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol 75(11):5240-5251. (Pubitemid 32448547)
34. Zalani S, Coppage A, Holley-Guthrie E, Kenney S (1997) The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter. J Virol 71(4):3268-3274. (Pubitemid 27119977)
35. Zalani S, Holley-Guthrie E, Kenney S (1995) The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J Virol 69(6):3816-3823.
36. Zalani S, Holley-Guthrie EA, Gutsch DE, Kenney SC (1992) The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factor. J Virol 66(12):7282-7292.
37. Panne D, Maniatis T, Harrison SC (2004) Crystal structure of ATF-2/c-Jun and IRF-3 bound to the interferon-beta enhancer. EMBO J 23(22):4384-4393. (Pubitemid 39601963)
38. Mueller N, et al. (1991) Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int J Cancer 49(3):387-393.
39. de-Thé G, et al. (1978) Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274(5673):756-761.
40. Zeng Y, et al. (1985) Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 36(5): 545-547. (Pubitemid 16233512)
41. Old LJ, et al. (1966) Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci USA 56(6):1699-1704.